Check out the newest COMBACTE Video!

Watch Video
SAATELLITE
Current status: Recruitment Completed
combacte-net

Human Monoclonal Antibody Against Staphylococcus aureus Alpha Toxin in Mechanically Ventilated Adult Subjects

SAATELLITE is a Phase II, randomized, double-blind, placebo-controlled trial. Involving patients who are at high risk of developing ventilator-associated pneumonia in an intensive-care unit. The trial will test the safety, the pharmacokinetic and pharmacodynamic characteristics, and the efficacy of MEDI4893. A novel treatment that uses antibodies against S. aureus.

The power of antibodies

MEDI4893, developed by MedImmune, the global biologics research and development arm of AstraZeneca, is a promising monoclonal antibody against S. aureus alpha toxin. The toxin kills cells in patients and damages tissues and organs, which helps microbes to spread and cause serious infections and disease. MEDI4893 uses an antibody – not an antibiotic – against this alpha toxin. Prevention would work against S. aureus, regardless of whether this bug is resistant to antibiotics. Another benefit is that this antibody approach is not expected to lead to new antibiotic resistance.

Study information

The study will test MEDI4893 in approximately 450 adult patients, in 60 to 80 ICUs across Europe. Patients in intensive-care units who need mechanical ventilation will be tested for the presence of S. aureus in their lower airways before they have developed a full-fledged infection and pneumonia. If they test positive, they will receive a single intravenous dose of MEDI4893 antibody. Which protects them from developing pneumonia.

Study team members

  • Bruno Francois

    Principal Investigator / Academic leader / Centre Hospitalier Universitaire de Limoges

Study level information

General information
  • Study NO NCT02296320
  • Study Name SAATELLITE
  • Study Type Phase II
  • Study Status Recruitment Complete
  • Enrollment Period 10/14 - 12/18
Enrollment
  • Total subjects planned 285
  • Total subjects screened 767
  • Total subjects enrolled 213
  • Total subjects completed 118

Study timeline

Light blue
Preparation phase
Dark blue
Trial period

Country level information

Filter
Sites planned 9
Sites activated 6
Belgium
Subjects
planned
0
Subjects
enrolled
26
Subjects
completed
10
Subjects completed
0.0%
Sites planned 9
Sites activated 6
Czech Republic
Subjects
planned
0
Subjects
enrolled
5
Subjects
completed
2
Subjects completed
0.0%
Sites planned 22
Sites activated 12
France
Subjects
planned
0
Subjects
enrolled
109
Subjects
completed
77
Subjects completed
0.0%
Sites planned 10
Sites activated 4
Germany
Subjects
planned
0
Subjects
enrolled
3
Subjects
completed
0
Subjects completed
0.0%
Sites planned 8
Sites activated 4
Greece
Subjects
planned
0
Subjects
enrolled
4
Subjects
completed
1
Subjects completed
0.0%
Sites planned 4
Sites activated 2
Hungary
Subjects
planned
0
Subjects
enrolled
3
Subjects
completed
0
Subjects completed
0.0%
Sites planned 1
Sites activated 1
Portugal
Subjects
planned
0
Subjects
enrolled
2
Subjects
completed
0
Subjects completed
0.0%
Sites planned 0
Sites activated 0
Romania
Subjects
planned
0
Subjects
enrolled
0
Subjects
completed
0
Subjects completed
0.0%
Sites planned 11
Sites activated 9
Spain
Subjects
planned
0
Subjects
enrolled
35
Subjects
completed
18
Subjects completed
0.0%
Sites planned 3
Sites activated 3
Switzerland
Subjects
planned
0
Subjects
enrolled
16
Subjects
completed
10
Subjects completed
0.0%
Sites planned 6
Sites activated 0
Great Britain
Subjects
planned
0
Subjects
enrolled
0
Subjects
completed
0
Subjects completed
0.0%